In addition, lymphangiogenic therapy with vascular endothelial growth factor receptor 3 (VEGFR3)-specific vascular endothelial growth factor C (VEGF-C) protein improved LV function after MI in mice9 and resolved cardiac edema and fibrosis in rats16. Here, FLT4 is linked to myocardial infarction.